Empirical Ventures

OSSTEC specializes in advanced technology for orthopedic applications, focusing on the development of metal 3D printed bone healing implants. These innovative implants are designed to mimic the natural structure of bone, addressing the high failure rates associated with traditional orthopedic solutions. By stimulating long-term bone growth, OSSTEC's products aim to improve the quality of life for patients suffering from conditions such as osteoarthritis, enabling them to remain active and pain-free. The company's commitment to enhancing bone healing technology positions it as a key player in the orthopedic market.

Exciting Instruments Limited is a joint venture based in Sheffield, combining the software expertise of Bulldozer Limited with Dr. Timothy Craggs' specialization in single-molecule technology. The company develops advanced single-molecule spectroscopy instruments that facilitate the discovery processes in biophysics, life sciences, drug discovery, and medical diagnostics. Their bench-top instruments are designed for two-color, single-molecule fluorescence detection, enabling scientific researchers to conduct real-time data analysis and visualization. With a focus on cloud connectivity and innovative software solutions, Exciting Instruments aims to streamline research and enhance the capabilities of scientific inquiry.

Silveray specializes in the development of affordable large-area direct conversion detectors for the X-ray imaging market. The company employs advanced technology that utilizes nanoparticle-based X-ray conversion materials, produced as semiconductor ink, which are then deposited onto a pixel backplane. This innovative approach enables high-performance X-ray imaging and generates an electrical current in response to detected X-ray photons. By focusing on sustainability and cost-effectiveness, Silveray aims to enhance imaging capabilities for healthcare and various industries.

MintNeuro is a healthcare company focused on neuroscience and microtechnology, specifically developing minimally invasive neural implants. These implants are designed to sense and modulate brain activity, offering a more precise treatment for various neurological conditions. By leveraging a platform technology for tiny implantable devices, MintNeuro aims to provide effective solutions that enhance patient outcomes while minimizing invasiveness. The company is committed to advancing the field of neurotechnology to improve the quality of care for individuals with neurological disorders.

Neuronostics Ltd is a spin-out from the University of Exeter in the UK, dedicated to developing and commercializing an innovative technology for assessing seizure susceptibility, known as BioEP. The company focuses on diagnosing and prognosing neurological conditions, particularly epilepsy. Its platform utilizes a patented method to calculate a seizure risk score based on routine electroencephalogram (EEG) recordings. This approach aims to enhance early diagnosis and prognosis of epilepsy, thereby enabling healthcare professionals to improve patient quality of life through more informed clinical decisions.

WASE is a London-based company founded in 2017 that specializes in decentralized sanitation systems aimed at promoting circular waste treatment. The company focuses on enhancing energy recovery from previously non-viable waste streams through its innovative waste-to-energy technology. In addition to energy recovery, WASE also recovers water and nutrients from waste, which can be transformed into fertilizers. By providing these solutions, WASE empowers clients to harness the potential of waste, contributing to more sustainable practices in waste management and resource recovery.

MitoRx Therapeutics is a biotechnology company that focuses on developing innovative therapeutics aimed at reversing mitochondrial dysfunction. The company targets various conditions, including neuromuscular disorders, metabolic diseases, and dementia. By specializing in mitochondrial-protective therapies, MitoRx seeks to address the underlying causes of these challenging diseases. The company is committed to both developing treatments for rare indications and forming partnerships to tackle broader health issues. Through its efforts, MitoRx aims to enable healthcare professionals to halt the progression of conditions associated with dystrophy and neurodegeneration.

Albotherm specializes in developing and manufacturing innovative passive cooling polymer coatings aimed at addressing climate change and its effects. The company's core technology is a smart transitioning coating that regulates surface temperatures without requiring any energy input. This coating reversibly changes from clear to white when temperatures exceed a specified trigger point, effectively reflecting unwanted light to mitigate overheating. This unique capability enables a range of industries to enhance thermal management in their structures and surfaces, contributing to energy efficiency and climate resilience.

Zentraxa is a developer of biopolymers focused on advancing medical processes and functions. Utilizing its proprietary technological platform, Zentide, the company specializes in the design, production, and testing of complex novel peptides. This innovative platform enables Zentraxa to overcome traditional bio-design limitations associated with conventional peptide synthesis, employing a universal process that enhances efficiency and versatility. Additionally, Zentraxa's unique manufacturing techniques facilitate the creation of biological adhesives, providing valuable support for various research and development initiatives in the medical field.

OSSTEC specializes in advanced technology for orthopedic applications, focusing on the development of metal 3D printed bone healing implants. These innovative implants are designed to mimic the natural structure of bone, addressing the high failure rates associated with traditional orthopedic solutions. By stimulating long-term bone growth, OSSTEC's products aim to improve the quality of life for patients suffering from conditions such as osteoarthritis, enabling them to remain active and pain-free. The company's commitment to enhancing bone healing technology positions it as a key player in the orthopedic market.

EnsiliTech is a biopharmaceutical company focused on preserving the integrity of vaccines and other biological materials. It has developed a healthcare technology that aims to prevent vaccine spoilage through a novel ensilication process. This technology involves the growth of protective silica nanoshells on the surface of vaccine components, which helps safeguard a variety of biomolecules from environmental degradation. By enhancing the shelf-life of vaccines, EnsiliTech's platform enables clients to minimize wastage and improve global vaccine accessibility.

QV Bioelectronics is focused on improving the lives of brain tumor patients through its innovative electric field therapy implant, GRACE. Developed in collaboration with leading neurosurgeons in the UK, GRACE aims to extend the life expectancy of glioblastoma patients, a group historically faced with limited treatment options and poor survival rates. Recognizing the urgent need for effective therapies, co-founders Dr. Richard Fu and Dr. Chris Bullock created a solution to address both the clinical and quality of life challenges faced by patients. The company has garnered nearly $1 million in funding from UK institutions, including Innovate UK, and over $1 million in equity funding from international life science investors. With a multidisciplinary team based in Alderley Park, Cheshire, QV Bioelectronics is dedicated to advancing GRACE from research to clinical application, utilizing cutting-edge materials science to enhance treatment outcomes for patients.

cheMastery Group Ltd. is a Glasgow-based company that specializes in laboratory automation technology specifically designed for the chemical sector. Founded in 2019, the company offers research and experimental development services, focusing on enhancing the efficiency and reliability of manufacturing and research processes in chemical laboratories. By providing automation solutions, cheMastery aims to streamline scientific workflows, making them more effective for researchers and scientists in the natural sciences and engineering industries.

Transdermal Diagnostics is a technology company focused on enhancing the prevention, diagnosis, and management of chronic conditions, particularly diabetes. The firm has developed a wearable technology platform that facilitates needle-free and continuous monitoring of blood sugar levels. This is achieved through the use of affordable disposable patches, which provide users with valuable biological insights. By enabling individuals with diabetes and prediabetes to monitor their condition more effectively, Transdermal Diagnostics aims to empower users to make informed decisions that contribute to healthier lifestyles.

Muddy Machines develops autonomous robots aimed at assisting farms with labor-intensive crops by automating fieldwork. The company initially focuses on its green asparagus harvest technology while planning to expand its capabilities to other crops. Additionally, Muddy Machines is exploring the use of its robotic platform for other labor-intensive tasks, such as weeding and precision applications. The robots utilize computer vision and machine learning to assess crop maturity and perform selective harvesting, ensuring that crops are picked with care to minimize damage. This innovation enables farmers to increase local produce yields and maintain the freshness of their crops.

MitoRx Therapeutics is a biotechnology company that focuses on developing innovative therapeutics aimed at reversing mitochondrial dysfunction. The company targets various conditions, including neuromuscular disorders, metabolic diseases, and dementia. By specializing in mitochondrial-protective therapies, MitoRx seeks to address the underlying causes of these challenging diseases. The company is committed to both developing treatments for rare indications and forming partnerships to tackle broader health issues. Through its efforts, MitoRx aims to enable healthcare professionals to halt the progression of conditions associated with dystrophy and neurodegeneration.

WASE is a London-based company founded in 2017 that specializes in decentralized sanitation systems aimed at promoting circular waste treatment. The company focuses on enhancing energy recovery from previously non-viable waste streams through its innovative waste-to-energy technology. In addition to energy recovery, WASE also recovers water and nutrients from waste, which can be transformed into fertilizers. By providing these solutions, WASE empowers clients to harness the potential of waste, contributing to more sustainable practices in waste management and resource recovery.

Anaphite Limited, established in 2016 and located in Bristol, United Kingdom, focuses on the development of graphene-based nanomaterials. The company specializes in creating graphene-enhanced cathodes designed for high-power, high-energy, and cost-effective lithium-ion batteries. Anaphite's innovative approach involves integrating graphene into composite materials through a scalable and economical process. This technology results in advanced properties that make their nanomaterials suitable for a variety of applications, including energy storage, air purification, and thermal management. By prioritizing affordability and versatility, Anaphite aims to make significant contributions to the commercialization of these technologies.

Argonaute RNA focuses on developing therapeutic medicines that utilize RNA interference (RNAi) to inhibit specific gene expression and combat various illnesses. The company has created a proprietary modification of small interfering RNA (siRNA) that enhances the stability of these molecules, addressing common challenges in the field. This innovative approach allows for the safe and effective silencing of targeted genes, ultimately preventing the production of specific proteins associated with life-threatening diseases. By building on existing intellectual property, Argonaute RNA aims to leverage its platform to deliver meaningful therapeutic solutions that harness the body's natural cellular mechanisms.